Eugene institute takes part in cancer drug study

Eugene institute takes part in cancer drug study »Play Video
Betty Hemmingsen is a patient at Willamette Valley Cancer Institute

EUGENE, Ore. - After the first two weeks, Betty Hemmingsen felt no side effects from Gazyva - other than her cancer going "inactive."

Hemmingsen is a patient at Willamette Valley Cancer Institute, which was involved in the first North American study of Gazyva. Ten of the initial 80 patients were here in Eugene.

According to the trial run, Gazyva showed an 84 percent reduction in the risk of disease worsening or death when combined with chemo compared to chemo alone.

Gazyva is the first medicine approved with the FDA's Breakthrough Therapy designation.